PERIOP 2 - LMWH 与安慰剂桥接疗法对需要暂时中断华法林的长期华法林患者的安全性和有效性。
一项针对动脉血栓栓塞高危患者(PERIOP 2)的术后低分子肝素桥接疗法与安慰剂桥接疗法的双盲随机对照试验
研究概览
详细说明
越来越多的患者接受长期华法林治疗以预防动脉血栓栓塞。 目前围手术期抗凝管理的方法(即 低分子肝素 (LMWH) 的“桥接疗法”)尚未标准化,也未通过充分的随机研究进行评估。 然而,大多数临床医生推荐桥接疗法。
我们最近完成了一项关于 LMWH 桥接疗法的多中心单臂试验研究。 这项在 10 个中心开展的研究在 10 个月内纳入了 224 名患者。 在初步研究中,术后血栓栓塞事件发生率为 3.1%,其中 75% 发生在因出血而停止抗凝治疗的患者中。
设计:前瞻性多中心随机双盲对照试验。 患者:来自加拿大 11 家教学医院的连续合格且同意的患者。 共有 1773 名接受华法林长期口服抗凝治疗的人工心脏瓣膜患者或患有心房颤动/扑动和主要危险因素的患者需要择期非心脏手术或侵入性手术,从而需要逆转口服抗凝治疗。
治疗方案:将在术前获得同意,但在确认合格后将在术后进行随机化。
术前期:在所有参与者中,华法林治疗将在手术前五天停止。 达肝素是一种 LMWH,将在手术前三天(但不包括手术当天)的清晨以 200 IU/kg 皮下给药,手术前一天除外,剂量为 100 I.U./kg术前24小时。 华法林将在手术当晚恢复。
术后期间:每日给药达肝素或安慰剂(从手术后的早晨开始),前提是达到手术止血,持续至少四天,直至 INR > 2.0。 被认为具有术后大出血高风险的患者将接受每日 5,000 IU sc 剂量的达肝素或安慰剂。 接受被认为出血并发症风险低的手术的患者将以 200 IU/Kg s.c. 的剂量恢复达肝素或安慰剂。 日常的。
结果:主要结果是随机分组后 90 天随访期内主要血栓栓塞事件的发生频率。 次要结果将包括大出血和总生存期。
相关性:桥接或不桥接是一个常见的临床问题,没有随机试验证据来指导临床医生。 该随机对照试验将回答术后桥接是否会降低血栓栓塞的风险或造成伤害。
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 2Y9
- QE II Health Sciences Centre
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8L 2X2
- Hamilton Health Sciences Corporation-General Hospital
-
Hamilton、Ontario、加拿大、L8N 3Z5
- Hamilton Health Sciences Corporation-McMaster Site
-
Hamilton、Ontario、加拿大、L8V 1C3
- Hamilton Health Sciences Corporation-Henderson Site
-
Ottawa、Ontario、加拿大、K1H 8L6
- Ottawa Hospital-General Campus
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- SMBD Jewish General Hospital
-
-
-
-
-
New Delhi、印度、110060
- Sir Ganga Ram Hospital
-
-
Nampally
-
Hyderabad、Nampally、印度、500001
- Care Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- 知情同意,
- 年龄 >18 岁的患者
- 人工(机械)心脏瓣膜患者
- 心房颤动或心房扑动和主要危险因素(既往 TIA 或中风、高血压、糖尿病、年龄 >75 岁、中度/重度左心室功能不全)患者
- 正在接受长期口服抗凝药并需要选择性非心脏手术或侵入性手术以逆转抗凝治疗的患者。
排除标准:
- 在停用华法林前的最后 30 天内有活动性出血的证据。
- 血小板计数 <100 x 109/L。
- 脊柱或神经外科。
- 预期寿命不到3个月。
- 计算的肌酐清除率 <30 毫升/分钟
- 需要心脏手术的患者。
- 多个假体(机械)瓣膜或 Starr-Edwards 瓣膜或具有中风或 TIA 病史的假体(机械)瓣膜
- 肝素诱导的血小板减少症 (HIT) 病史
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:平行线
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
ACTIVE_COMPARATOR:1个
术后患者随机接受积极治疗或安慰剂。 积极治疗是注射达肝素。 随机接受积极治疗的患者将接受达肝素 5,000 iu 或 200 iu/kg,每天一次,具体取决于他们接受的手术类型。 |
皮下注射 5,000 iu 或 200 iu/kg,具体取决于手术类型,每天一次,至少持续 4 天或直至 INR 为 2.0
其他名称:
|
实验性的:2个
患者将在术后随机接受积极治疗或安慰剂
|
术后患者将被随机分配接受积极治疗或安慰剂。 安慰剂每天一次皮下注射。根据手术类型,安慰剂的量将等同于积极治疗。 IE。 5,000 国际单位或 200 国际单位/公斤 |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
主要血栓栓塞症
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
次要结果测量
结果测量 |
大体时间 |
---|---|
大出血
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
轻微出血
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
大出血和主要血栓栓塞事件的复合
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
轻微血栓栓塞事件
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
总体生存。
大体时间:随机分组后 90 天
|
随机分组后 90 天
|
合作者和调查者
调查人员
- 首席研究员:Michael J Kovacs, MD, FRCPC、University of Western Ontario, Canada
出版物和有用的链接
一般刊物
- Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
- Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med. 2003 Feb 10;163(3):293-7. doi: 10.1001/archinte.163.3.293.
- Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997 May 22;336(21):1506-11. doi: 10.1056/NEJM199705223362107. No abstract available.
- Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med. 1996 Aug 8;335(6):407-16. doi: 10.1056/NEJM199608083350607. No abstract available.
- Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994 Feb;89(2):635-41. doi: 10.1161/01.cir.89.2.635.
- White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995 Jan 1;122(1):40-2. doi: 10.7326/0003-4819-122-1-199501010-00006.
- Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E, Wells PS. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003 May 6;138(9):714-9. doi: 10.7326/0003-4819-138-9-200305060-00007.
- Madura JA, Rookstool M, Wease G. The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg. 1994 Jul;60(7):542-6; discussion 546-7.
- Eckman MH, Beshansky JR, Durand-Zaleski I, Levine HJ, Pauker SG. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? JAMA. 1990 Mar 16;263(11):1513-21.
- Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J. 1978 Aug;96(2):163-5. doi: 10.1016/0002-8703(78)90080-7.
- Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 1995 Oct;108(4 Suppl):371S-379S. doi: 10.1378/chest.108.4_supplement.371s. No abstract available. Erratum In: Chest 1996 Feb;109(2):592.
- Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest. 1999 Nov;116(5):1240-6. doi: 10.1378/chest.116.5.1240.
- Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003 Apr 28;163(8):901-8. doi: 10.1001/archinte.163.8.901.
- Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004 Jun 28;164(12):1319-26. doi: 10.1001/archinte.164.12.1319.
- Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999 Aug 15;84(4):478-80, A10. doi: 10.1016/s0002-9149(99)00341-0.
- Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004 Sep 21;110(12):1658-63. doi: 10.1161/01.CIR.0000142859.77578.C9. Epub 2004 Sep 13.
- Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 2003 May;89(5):527-30. doi: 10.1136/heart.89.5.527.
- Omran H, Hammerstingl C, Schmidt H, von der Recke G, Paar WD, Luderitz B. A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost. 2003 Aug;90(2):267-71. doi: 10.1160/TH02-10-0159.
- Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001 Jun;35(6):669-74. doi: 10.1345/aph.10305.
- POLLER L, THOMSON J. EVIDENCE FOR
- Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J. 1991 Nov;12(11):1225-33. doi: 10.1093/eurheartj/12.11.1225.
- Palareti G, Legnani C, Guazzaloca G, Frascaro M, Grauso F, De Rosa F, Fortunato G, Coccheri S. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants--a prospective study. Thromb Haemost. 1994 Aug;72(2):222-6.
- Valles J, Aznar J, Santos T, Villa P, Fernandez A. Platelet function in patients with chronic coronary heart disease on long-term anticoagulant therapy: effect of anticoagulant stopping. Haemostasis. 1993 Jul-Aug;23(4):212-8. doi: 10.1159/000216877.
- Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 1;85(11):3034-9.
- Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996 Feb;92(2):479-85. doi: 10.1046/j.1365-2141.1996.d01-1499.x.
- Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996 Sep 7;348(9028):633-8.
- Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997 Sep 4;337(10):688-98. doi: 10.1056/NEJM199709043371007. No abstract available. Erratum In: N Engl J Med 1997 Nov 20;337(21):1567.
- Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res. 1998 Aug 1;91(3):137-42. doi: 10.1016/s0049-3848(98)00083-8.
- Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
- Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996 Mar 2;347(9001):561-8.
- Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996 Mar 14;334(11):677-81. doi: 10.1056/NEJM199603143341101.
- Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996 Mar 14;334(11):682-7. doi: 10.1056/NEJM199603143341102. Erratum In: N Engl J Med 1997 Oct 23;337(17):1251.
- Columbus Investigators; Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997 Sep 4;337(10):657-62. doi: 10.1056/NEJM199709043371001.
- Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997 Sep 4;337(10):663-9. doi: 10.1056/NEJM199709043371002.
- Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2003:520-39. doi: 10.1182/asheducation-2003.1.520.
- Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. doi: 10.1378/chest.126.3_suppl.188S.
- Kearon C, Hirsh J. Perioperative management of patients receiving oral anticoagulants. Arch Intern Med. 2003 Nov 10;163(20):2532-3; author reply 2533. doi: 10.1001/archinte.163.20.2532-b. No abstract available.
- Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 Jul 11;154(13):1449-57. Erratum In: Arch Intern Med 1994 Oct 10;154(19):2254.
- Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet. 2000 Nov 4;356(9241):1551-3. doi: 10.1016/S0140-6736(00)03125-1.
- Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Aug 14;349(7):631-9. doi: 10.1056/NEJMoa035422.
- Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. doi: 10.1056/NEJMoa035241. Erratum In: N Engl J Med. 2003 Dec 25;349(26):2577. N Engl J Med. 2004 Jul 8;351(2):200.
- Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002 Sep;33(9):2243-6. doi: 10.1161/01.str.0000027437.22450.bd.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7. doi: 10.1161/01.str.19.5.604.
- Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ. 1998 Oct 20;159(8):931-8.
- Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30;349(18):1695-702. doi: 10.1056/NEJMoa035451. Erratum In: N Engl J Med. 2004 Jan 22;350(4):423.
- Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, Blostein M, Kahn SR, Schulman S, Sabri E, Solymoss S, Ramsay T, Yeo E, Rodger MA; PERIOP2 Investigators. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021 Jun 9;373:n1205. doi: 10.1136/bmj.n1205.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.